A new report from the American Cancer Association predicts lung cancer will cause more deaths than any other in 2026.

Control of PRRSV, PCV2, IAV through vaccination, management and disease elimination most effective way of preventing the ...

Discover the hidden triggers of idiopathic pulmonary fibrosis (IPF) in your home. Learn to minimize risks from scents, cleaning products, allergens, GERD, and infections.

Findings Show Xenon MRI Ventilation Defects Independently Predicts Exacerbation Risk Beyond Conventional Clinical Measures ...

Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

Global pulmonary function testing market growth is driven by rising prevalence of chronic respiratory diseases, increasing geriatric population, and growing adoption of diagnostic monitoring ...

Estimated YUTREPIA net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in Jun ...

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year ...

When inflammation in the body goes unchecked, it can cause fibrosis, or tissue scarring that may lead to organ dysfunction or ...

Labcorp is a global leader of innovative and comprehensive laboratory services. The company's Venture Fund invests in and supports early stage, private companies that are focused on improving health ...

The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...